A new UK infectious diseases company,Poolbeg Pharma plc, is being spun out of the CRO, Open Orphan plc and, with a completed fund-raising, is planning to pursue a capital-light clinical model to develop therapeutic candidates that can subsequently be acquired by big pharma companies.
Poolbeg has raised funds from an initial public offering (IPO), and expects admission and trading on the London Stock Exchange’s junior
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?